Placebo-controlled trial of oral laquinimod for multiple sclerosis. - Wikidata - awgldk - TriplyDB

Placebo-controlled trial of oral laquinimod for multiple sclerosis.

Placebo-controlled trial of oral laquinimod for multiple sclerosis.

http://www.wikidata.org/entity/Q34261244

about

Neurodegeneration in multiple sclerosis: novel treatment strategies Multiple sclerosis in 2012: Novel therapeutic options and drug targets in MS Treatment with disease modifying drugs for people with a first clinical attack suggestive of multiple sclerosis Adverse effects of immunotherapies for multiple sclerosis: a network meta-analysis Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis Laquinimod for multiple sclerosis Pharmacological treatment for memory disorder in multiple sclerosis Laquinimod in the treatment of multiple sclerosis: a review of the data so far Optimizing treatment success in multiple sclerosis Remyelination Therapy in Multiple Sclerosis Kynurenines and Multiple Sclerosis: The Dialogue between the Immune System and the Central Nervous System Optimizing therapeutics in the management of patients with multiple sclerosis: a review of drug efficacy, dosing, and mechanisms of action Remyelination therapy for multiple sclerosis Multiple sclerosis-a quiet revolution Relating relapse and T2 lesion changes to disability progression in multiple sclerosis: a systematic literature review and regression analysis New and emerging immune-targeted drugs for the treatment of multiple sclerosis Regression to the mean and predictors of MRI disease activity in RRMS placebo cohorts--is there a place for baseline-to-treatment studies in MS?Benefits versus risks of latest therapies in multiple sclerosis: a perspective review Pharmacological Approaches to Delaying Disability Progression in Patients with Multiple Sclerosis Small molecules in the treatment of systemic lupus erythematosus Multiple sclerosis: molecular mechanisms and therapeutic opportunities Review of daclizumab and its therapeutic potential in the treatment of relapsing-remitting multiple sclerosis NF-κB Pathways in the Pathogenesis of Multiple Sclerosis and the Therapeutic Implications Next-Generation Therapeutics for IBD Role of the immunogenic and tolerogenic subsets of dendritic cells in multiple sclerosis Laquinimod therapy in multiple sclerosis: a comprehensive review Cladribine tablets for the treatment of relapsing-remitting multiple sclerosis Therapeutic decisions in multiple sclerosis: moving beyond efficacy Current and emerging therapies in multiple sclerosis: a systematic review Placebo cohorts in phase-3 MS treatment trials - predictors for on-trial disease activity 1990-2010 based on a meta-analysis and individual case data Alemtuzumab for the treatment of relapsing-remitting multiple sclerosis: a review of its clinical pharmacology, efficacy and safety.Blinded and unblinded internal pilot study designs for clinical trials with count data.Natalizumab: a review of its use in the management of relapsing-remitting multiple sclerosis.Efficacy and safety of laquinimod in multiple sclerosis: current status Clinical relevance of brain volume measures in multiple sclerosis.MRI measures of neurodegeneration in multiple sclerosis: implications for disability, disease monitoring, and treatment.Therapeutic strategies for relapsing-remitting multiple sclerosis: a special focus on reduction of grey matter damage as measured by brain atrophy.Current, new and future biological agents on the horizon for the treatment of inflammatory bowel diseases.Infection risk in patients on multiple sclerosis therapeutics.Treating relapsing-remitting multiple sclerosis: therapy effects on brain atrophy.

P2860

Q22241472-81C6703B-A545-453B-A123-A9CE3D140CD6 Q22251014-C9DB86FF-8A1D-4567-9473-DC09C073D05F Q24185806-43FC4A85-09BF-4613-9382-ED3E127CECA2 Q24185820-90881C1C-6A9F-4EC8-893F-E28A084D38F0 Q24187126-13C44FD8-1698-4FF6-909B-A509625772B3 Q24200527-AB7429FA-1841-4B0A-9D3F-59332817406C Q24201735-023A1A56-6201-4D07-9FFC-220646FB7DF5 Q26752895-66544796-DB1A-4D46-9912-1CAEAAAE9F28 Q26771968-D65C0AB2-C358-4290-A974-717D12E570B7 Q26772359-D38DEAEA-594A-4542-9A6E-8643AF37C73D Q26796667-5BF63E1D-B2B0-4757-8F8B-E5FE574DDC61 Q26822611-A1248FBA-D4DF-4C15-AEA0-9549444119BC Q26824246-E73ADD66-1C92-42F3-97BB-E1241067BADF Q26826930-FC6AA71A-B2E0-4159-9AD1-730F571B59E3 Q26828463-7A4114CE-16D0-4BD9-B1FC-48BDFC8AA751 Q26997067-98843C20-89E6-46D5-9863-CAD74EBF867F Q26998513-286A6096-D9FA-4294-91C7-9BE84E33BCFC Q26999417-72E19CFD-4DB0-496B-A60D-BF942647F0D1 Q27000269-C50371AE-2E9F-42FB-941E-24453A7F0FC6 Q27010090-3C665C73-60ED-497D-9F18-C4BA480FD2A2 Q27023735-41C9BD58-EC1C-41E6-9B35-FECA7BA46C61 Q27693249-C9B90350-CAAD-4F14-A2C0-86C17FF3C2EF Q28078299-5E313B00-3CF4-43B8-9D5A-E69A7CF78BE6 Q28082306-8F27BB4F-0763-46C5-B2B2-096CE626A1E0 Q28082878-293EFEE2-7727-4733-8D70-23FF95590927 Q28086844-46B007C2-2DD3-499A-99A9-201DF4113C59 Q28281816-74E25804-C594-4357-8C4B-6FDA093DAA8E Q28541039-AE27442E-ABF7-41BA-8024-093BC05589CC Q29010983-86653957-D136-4A4E-B7F4-B888165B1771 Q30000824-2D6AC6B9-0A80-4E9B-8A35-F49B1DF34626 Q30458930-3AA07477-0649-40E6-9A95-4A40FA51A4FE Q30632186-1E8FDAC6-B80D-4CE5-841B-8E3254D9828E Q30659100-D5910B57-3C52-4312-A90D-74E1394D79EB Q30694702-748343BA-9924-4A61-91BA-C49FAE1D43E8 Q30738659-67AF6F92-5A7B-4A18-AFD3-9B3B73A32731 Q30798662-DD25FB30-E3E0-4C04-9A2D-D56EA9294DB2 Q30869048-689FB884-DC48-4645-9161-981C81C51E3B Q30902172-0E03F3AB-B8EF-4F85-BEC9-CDBAC74648AC Q30908652-C55C25DC-9741-4695-A200-45683E99E2E6 Q30965003-B4030971-6C41-4E04-9756-43796518DA1C

P2860

Placebo-controlled trial of oral laquinimod for multiple sclerosis.

http://www.wikidata.org/entity/Q34261244

description

2012 nî lūn-bûn

@nan

2012 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի մարտին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Placebo-controlled trial of oral laquinimod for multiple sclerosis.

@ast

Placebo-controlled trial of oral laquinimod for multiple sclerosis.

@en

Placebo-controlled trial of oral laquinimod for multiple sclerosis.

@nl

type

label

Placebo-controlled trial of oral laquinimod for multiple sclerosis.

@ast

Placebo-controlled trial of oral laquinimod for multiple sclerosis.

@en

Placebo-controlled trial of oral laquinimod for multiple sclerosis.

@nl

prefLabel

Placebo-controlled trial of oral laquinimod for multiple sclerosis.

@ast

Placebo-controlled trial of oral laquinimod for multiple sclerosis.

@en

Placebo-controlled trial of oral laquinimod for multiple sclerosis.

@nl

P1433

Q34261244-16C4F27C-6089-4085-8D6B-21AC5CF7ADAB

P1476

Q34261244-BF83569F-B05E-4DD6-98CD-EEA0B878DCA8

P2093

Q34261244-386BAAFD-3902-47BC-B0AA-DDF27D784C99

Q34261244-3AB9A614-EDFD-4E80-B897-EE2E7DCE4363

Q34261244-4D8B7A11-5357-4B4B-BC17-79227C1187F1

Q34261244-AE450B81-95F2-49A7-AA10-E5800C937926

Q34261244-DEB97440-8F32-46D9-8385-3DA9FC477FB6

Q34261244-F06697E3-7E3B-443C-957C-E3001D3DC859

P304

Q34261244-51916AB6-3317-4AC6-A545-7A1080E713E0

P31

Q34261244-85ED4365-AF27-44F5-A533-4453474BAAE1

P356

Q34261244-B25420FB-1BEA-4BBB-A286-DD9773D967D4

P407

Q34261244-6785CAFC-BF61-4DA2-BE03-9D77FCED81F5

P433

Q34261244-8917385B-849A-4B47-BFEE-F2B0CFE44D7F

P478

Q34261244-882ED11A-EAC7-4D5C-AE14-94B967C8C716

P50

Q34261244-841FE141-764D-4CEE-AB0C-800408898FD8

Q34261244-D60C587E-1CA2-40F3-877C-A17920A1C23A

P577

Q34261244-E40B9AEB-845C-49E2-BE65-6573D6D4CDEC

P698

Q34261244-8C7C3472-6B8E-4152-86FB-CE377186CD0B

P921

Q34261244-13E7FEFB-3C1E-4E96-9C63-6DA0432BE36A

Q34261244-BC0A614C-D495-4EB2-AA03-3E1CA243F703

P356

P1433

The New England Journal of Medicine

P1476

Placebo-controlled trial of oral laquinimod for multiple sclerosis.

@en

P2093

ALLEGRO Study Group

http://www.w3.org/2001/XMLSchema#string

Alexey Boyko

http://www.w3.org/2001/XMLSchema#string

Douglas Jeffery

http://www.w3.org/2001/XMLSchema#string

Maria A Rocca

http://www.w3.org/2001/XMLSchema#string

Massimo Filippi

http://www.w3.org/2001/XMLSchema#string

Xavier Montalban

http://www.w3.org/2001/XMLSchema#string

P304

1000-1009

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1056/NEJMOA1104318

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

366

http://www.w3.org/2001/XMLSchema#string

P50

P577

2012-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22417253

http://www.w3.org/2001/XMLSchema#string

P921

multiple sclerosis